日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Single-cell atlas of human liver and blood immune cells across fatty liver disease stages reveals distinct signatures linked to liver dysfunction and fibrogenesis

脂肪肝疾病各阶段人类肝脏和血液免疫细胞的单细胞图谱揭示了与肝功能障碍和纤维化相关的独特特征

期刊:Nature Immunology
影响因子:27.6
doi:10.1038/s41590-025-02255-y
Martin, Owen P; Wallace, Michael S; Oetheimer, Christopher; Patel, Hailey B; Butler, Michael D; Wong, Lai Ping; Huang, Pinzhu; Elbaz, Joshua; Costentin, Charlotte; Salloum, Shadi; Reinus, Zoe; Obinelo, Adaeze; Kim, Ulandt; Shroff, Stuti; Corey, Kathleen E; Popov, Yury V; Charles, Edgar D; Sadreyev, Ruslan I; Chung, Raymond T; Alatrakchi, Nadia
代谢
脂肪肝
免疫/内分泌
细胞生物学
单细胞
发表日期：2025
文献求助 收藏

Quantitation of Alzheimer's disease biomarkers in plasma using SMC(®) high sensitivity immunoassays

利用SMC®高灵敏度免疫测定法定量检测血浆中阿尔茨海默病生物标志物

期刊:Jhep Reports
影响因子:7.5
doi:10.1016/j.jhepr.2022.100661
Brown, Elizabeth A; Minnich, Anne; Sanyal, Arun J; Loomba, Rohit; Du, Shuyan; Schwarz, John; Ehman, Richard L; Karsdal, Morten; Leeming, Diana J; Cizza, Giovanni; Charles, Edgar D; Hwang, Joseph; Gitan, Raad; Droll, Deborah; Adkisson, Elizabeth; Wiese, Rick
阿尔茨海默症
免疫/内分泌
发表日期：2025
文献求助 收藏

Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial

Cendakimab治疗中重度特应性皮炎患者：一项随机临床试验

期刊:Jama Dermatology
影响因子:11
doi:10.1001/jamadermatol.2024.2131
Blauvelt, Andrew; Guttman-Yassky, Emma; Lynde, Charles; Khattri, Saakshi; Schlessinger, Joel; Imafuku, Shinichi; Tada, Yayoi; Morita, Akimichi; Wiseman, Marni; Kwiek, Bartlomiej; Machkova, Martina; Zhang, Peijin; Linaberry, Misti; Li, Jie; Zhang, Sandra; Franchin, Giovanni; Charles, Edgar D; De Oliveira, Claudia H M C; Silverberg, Jonathan I
发表日期：2024
文献求助 收藏

Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment

在肝功能受损患者中评估BMS-986263（一种含有HSP47 siRNA的脂质纳米颗粒）的药代动力学、安全性和耐受性。

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.13581
Qosa, Hisham; de Oliveira, Claudia H M C; Cizza, Giovanni; Lawitz, Eric J; Colletti, Nicholas; Wetherington, Jeffrey; Charles, Edgar D; Tirucherai, Giridhar S
SP4
多发性硬化症
发表日期：2023
文献求助 收藏

BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial

BMS-986263治疗晚期肝纤维化患者：一项随机、安慰剂对照的II期试验的36周结果

期刊:Hepatology
影响因子:15.8
doi:10.1002/hep.32181
Lawitz, Eric J; Shevell, Diane E; Tirucherai, Giridhar S; Du, Shuyan; Chen, Warner; Kavita, Uma; Coste, Angie; Poordad, Fred; Karsdal, Morten; Nielsen, Mette; Goodman, Zachary; Charles, Edgar D
多发性硬化症
发表日期：2022
文献求助 收藏

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis

培贝弗明可选择性地降低非酒精性脂肪性肝炎患者的继发性胆汁酸浓度

期刊:Jhep Reports
影响因子:7.5
doi:10.1016/j.jhepr.2021.100392
Luo, Yi; Decato, Benjamin E; Charles, Edgar D; Shevell, Diane E; McNaney, Colleen; Shipkova, Petia; Apfel, Abraham; Tirucherai, Giridhar S; Sanyal, Arun J
肝炎
发表日期：2022
文献求助 收藏

Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis

CCR2/CCR5拮抗剂与FGF21类似物联合治疗可协同改善脂肪性肝炎和纤维化

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms23126696
Puengel, Tobias; Lefere, Sander; Hundertmark, Jana; Kohlhepp, Marlene; Penners, Christian; Van de Velde, Frederique; Lapauw, Bruno; Hoorens, Anne; Devisscher, Lindsey; Geerts, Anja; Boehm, Stephanie; Zhao, Qihong; Krupinski, John; Charles, Edgar D; Zinker, Bradley; Tacke, Frank
CR2
CCR5
FGF21
FGF2
肝炎
发表日期：2022
文献求助 收藏

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH.

SOMAscan蛋白质组学鉴定出与NASH患者肝纤维化相关的血清生物标志物

期刊:Hepatology Communications
影响因子:4.6
doi:10.1002/hep4.1670
Luo Yi, Wadhawan Samir, Greenfield Alex, Decato Benjamin E, Oseini Abdul M, Collen Rebecca, Shevell Diane E, Thompson John, Jarai Gabor, Charles Edgar D, Sanyal Arun J
其它
发表日期：2021
文献求助 收藏

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

BMS-986278（一种溶血磷脂酸受体 1 (LPA(1)) 拮抗剂）在特发性肺纤维化 (IPF) 或进行性纤维化间质性肺病 (PF-ILD) 患者中的 II 期试验设计

期刊:Bmj Open Respiratory Research
影响因子:3.4
doi:10.1136/bmjresp-2021-001026
Corte, Tamera J; Lancaster, Lisa; Swigris, Jeffrey J; Maher, Toby M; Goldin, Jonathan G; Palmer, Scott M; Suda, Takafumi; Ogura, Takashi; Minnich, Anne; Zhan, Xiaojiang; Tirucherai, Giridhar S; Elpers, Brandon; Xiao, Hong; Watanabe, Hideaki; Smith, R Adam; Charles, Edgar D; Fischer, Aryeh
信号转导
多发性硬化症
特发性肺纤维化
发表日期：2021
文献求助 收藏

Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study

聚乙二醇化FGF21（Pegbelfermin，BMS-986036）治疗肥胖合并2型糖尿病患者：一项随机II期研究的结果

期刊:
影响因子:
doi:10.1002/oby.22344
Charles, Edgar D; Neuschwander-Tetri, Brent A; Pablo Frias, Juan; Kundu, Sudeep; Luo, Yi; Tirucherai, Giridhar S; Christian, Rose
糖尿病
FGF21
肥胖
代谢
多发性硬化症
FGF2
发表日期：2019
文献求助 收藏